Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using

Jia-Ning Zhang1,2, Feng Wei2, Lin-Han Lei3

  • 1The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.

Bioengineered
|November 17, 2021
PubMed

Insights

Cyclin-Dependent Kinase 4 (CDK4) is a key factor in hepatocellular carcinoma (HCC) progression. Targeting CDK4 can inhibit HCC cell invasion and metastasis, offering a potential therapeutic strategy for this deadly cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
  • HCC is characterized by high rates of invasion and metastasis.
  • Effective early intervention strategies are crucial for improving patient outcomes.

Purpose of the Study:

  • To identify prognostic factors for HCC using TCGA database.
  • To investigate the role of Cyclin-Dependent Kinase 4 (CDK4) in HCC invasion and metastasis.
  • To explore CDK4's regulatory pathways in HCC progression.

Main Methods:

  • Prognostic analysis using TCGA data (overall survival, disease-free survival).
  • mRNA and protein expression analysis of CDK4 in HCC tissues (immunohistochemistry, Western Blot).
  • Functional assays (Transwell assay) and bioinformatics analysis to assess CDK4's impact on HCC cell invasion, migration, and epithelial-mesenchymal transition (EMT).

Main Results:

  • CDK4 identified as an independent prognostic factor for HCC.
  • CDK4 expression is significantly upregulated in HCC tissues and increases with tumor stage.
  • Knocking down CDK4 suppresses HCC cell invasion and migration, and regulates EMT via the Wnt/β-catenin pathway.

Conclusions:

  • CDK4 is a crucial oncogene in HCC progression and metastasis.
  • CDK4 represents a potential therapeutic target for inhibiting HCC metastasis.
  • Further investigation of CDK4-associated genes is warranted for novel therapeutic strategies.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K